Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Fight Against Superbugs Hinges on Struggling Small Biotechs

Katherine Gemmell for Bloomberg Business writes about the latest research from the Access to Medicine Foundation.

Date

10 June 2021

Gemmell covers findings from the new report -- part of the Antimicrobial Resistance Benchmark research programme -- which looks into the crucial role that small- and medium-sized medicine makers play in providing the world's antibiotics. While these companies lead 75% of research and development efforts for new, desperately needed antibiotics that have lifesaving potential in the face of growing antimicrobial resistance, small companies are chronically under-funded and at risk of bankruptcy. 

Jayasree K. Iyer, Executive Director for the Access to Medicine Foundation, is quoted in the article: "The pandemic of drug-resistant infections will pose a bigger global health emergency than Covid-19, and it’s a silent pandemic that is already growing."

Click here to read the full article. 

Suzanne Wolf

Director of Communications

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved